FDA Accepts Supplemental New Drug Application for Gilead's Yeztugo
Gilead Sciences (NASDAQ:GILD) announced that the FDA accepted its supplemental new drug application for Yeztugo as a once-weekly oral PrEP treatment, with a PDUFA target action date of February 2027. This milestone could expand Gilead's HIV prevention portfolio and offer patients more convenient dosing options.
Tickers: $GILD